By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Start-up Blueprint Medicines today announced it has closed on a $40 million Series A round.

The round was led by Third Rock Ventures, and proceeds will be used to develop new cancer therapies using Blueprint's proprietary compound library and Insights-to-Validation platform that targets molecular drivers of cancer "and emerging resistance mechanisms unique to certain cancer patients," the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.